OBESITY TREATMENT

More in OBESITY TREATMENT

• Pfizer ends development of weight-loss pill danuglipron

  Danuglipron is part of a class of drugs designed to target an intestinal hormone called GLP-1.

  

• Lilly sues two compounders over copies of weight-loss drugs

  Lilly has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide.

  

• Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal

  Under the terms of the deal announced by Lexicon on Friday, Novo will get worldwide rights to develop, manufacture and commercialize the drug, LX9851, for obesity and associated metabolic disorders.

  

• Zerodha founder and CEO Nithin Kamath: This is closest thing we have seen to a Miracle Drug

  Insurance premiums have to change, and annuity payouts in pensions will have to be readjusted. What we don't know is more than what we know about these drugs at this point. Also, the patents on the active ingredient in this drug is expiring in 2026, which means, cheaper generics will be available. Is the world ready for this?, he wrote.

  

• Open to tie-ups in India for selling Mounjaro: Eli Lilly CEO David Ricks

  Eli Lilly's Mounjaro is priced at ₹14,000 for a month's dose in India at a low dose and that goes up to ₹17,500 for a higher dose. The same drug is priced at over $1,000 per month in the US.

  

• Merck buys rights to heart disease drug in latest China deal

  Most recently, Danish drugmaker Novo Nordisk bought global rights to China-based United Laboratories International's weight-loss drug candidate in a deal worth up to $2 billion.

  

• Mounjaro debuts in India: Eli Lilly’s blockbuster drug targets obesity and diabetes

  Mounjaro is indicated as an adjunct to a reduced-calorie diet for weight management in adults and is one of the best-selling drugs of US weight loss giant that generated more than $11 billion or around ₹94,600 crore in 2024.

  

• Lilly needs a plan to spur weight-loss drug sales, investors say

  Lilly, which reports its fourth-quarter earnings on Thursday, said in January that wholesalers had not restocked their Zepbound inventories as expected, driving shares down 8 per cent. It was the second time in a year its sales had come up short due to issues it attributed to the supply chain.

  

• About half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll finds

  When it comes to ages 12 to 18 who are dealing with obesity, Americans are divided: About one-third say the use of weight-loss drugs in this context is a "very" or "somewhat" good thing, a similar share say it's a bad thing and about 3 in 10 say it isn't good or bad.

  

• About half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll finds

  The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in popularity after the food and drug administration approved them for weight loss in 2021. Now, they're all over the place - celebrities, TV advertisements, social media, news media, your neighbor.

  

• Next-gen Novo Nordisk shot shows 22% weight loss in early results

  The weight loss, which compared with a decline of 2per cent in a placebo group, was seen in overweight or obese trial participants on weekly injections of Novo's experimental amycretin, which has a dual mode of action that the drugmaker is also testing in pill form.